MannKind | MNKD - Equity Capital And Reserves


MannKind reported $-44.55M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 431.19M 32.87M Sep/2025
Dynavax Technologies USD 534.14M 39.98M Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Insmed USD 945.57M 304.16M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
MannKind USD -44.55M 10.49M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Novo Nordisk DKK 26.56B 111.98B Jun/2025
Pfizer USD 92.8B 4.11B Sep/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Xencor USD 625.32M 4.96M Sep/2025